EGFR mAb associated PFS benefit was larger in those with KRAS WT tumours if they were aged 70 or younger (HRadj 0.68, p < 0.001) compared to those over 70 (HRadj 0.93, p = 0.465). Here, KRAS is linked to neoplasm.